Merck acquires global rights to SciBrunch Therapeutics’ SPR2015, a preclinical oral KRAS G12D inhibitor, in a deal worth up ...
Agenus Inc. has surged >195% YTD, driven by optimism around its BOT/BAL combo therapy for MSS colon cancer. Read more on AGEN ...
在KRAS G12D的争夺中，晚了一步的默沙东开始提速了。 今年1月，默沙东曾与Revolution 有一场传得沸沸扬扬的收购案，最终因估值未能达成一致，而无疾而终，想要在RAS大展拳脚的默沙东也不得不放缓脚步。
KFF Health News on MSN
How much of a cancer drug is too much? Patients, researchers challenge FDA-approved dosages
How much of a cancer drug is too much? Patients, researchers challenge FDA-approved dosages Northwestern University economist Chuck Manski studies decision-making amid uncertainty. That prepared him ...
Following is a summary of current health news briefs. Too weak, too strict: India's food warning labels draw fire from all ...
FDA Approves WELIREG Plus LENVIMA for Certain Previously Treated Adult Patients With Advanced Renal Cell Carcinoma With a Clear Cell Component (ccRCC) ...
La société biopharmaceutique Celltrion prévoit de racheter 560 853 actions ordinaires pour un montant maximal de 100 milliards de wons entre le 30 septembre et le 29 décembre, afin ...
Merck & Co., Inc. (NYSE:MRK) and Daiichi Sankyo announced on September 25 that they voluntarily withdrew the U.S. application ...
Overton’s nomination has been criticized by abortion rights groups. In a statement released Thursday, Reproductive Freedom ...
Patients with bladder cancer being treated with the immunotherapy agent, Keytruda, should not hesitate to call their oncology team if something does not feel right, an expert said. Patients with ...
La empresa biofarmacéutica Celltrion planea recomprar 560.853 acciones ordinarias por un importe de hasta 100.000 millones ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results